Search

Your search keyword '"Tarantino, V"' showing total 8 results
Start Over Author "Tarantino, V" Publisher wiley
8 results on '"Tarantino, V"'

1. PROGNOSTIC FACTORS, MANAGEMENT AND OUTCOME OF AN INTERNATIONAL SERIES OF 41 PATIENTS WITH PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMLBCL) AND CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT

Author

Ferreri, A. J.M., primary, Tarantino, V., additional, Cabras, G., additional, Ferrara, F., additional, Zinzani, P. L., additional, Arcaini, L., additional, Castellino, A., additional, Tucci, A., additional, Cocito, F., additional, Davies, A., additional, Salvador Chalup, M. M.B, additional, Cwynarski, K., additional, Nogueira, F. L., additional, Petrucci, L., additional, Muzi, C., additional, Onofrillo, D., additional, Ferrario, A., additional, Ramakrishnan, P., additional, Scalzulli, P. R., additional, Tani, M., additional, Tisi, M. C., additional, Papageorgiou, S. G., additional, Calimeri, T., additional, Angelillo, P., additional, Foppoli, M., additional, Dimou, M., additional, Ponzoni, M., additional, Iannitto, E., additional, and Vassilakopoulos, T. P., additional

Published
2021
Full Text
View/download PDF

2. EARLY METABOLIC RESPONSE IN FOLLICULAR LYMPHOMA: A SUBSET ANALYSIS OF THE FOLL12 TRIAL BY THE FONDAZIONE ITALIANA LINFOMI (FIL)

Author

Luminari, S., primary, Guerra, L., additional, Durmo, R., additional, Chauvie, S., additional, Peano, S., additional, Franceschetto, A., additional, Fallanca, F., additional, Tarantino, V., additional, Pinto, A., additional, Ghiggi, C., additional, Pulsoni, A., additional, Merli, M., additional, Farina, L., additional, Tani, M., additional, Botto, B., additional, Musuraca, G., additional, Falini, B., additional, Ballerini, F., additional, Stefani, P. M., additional, Bolis, S., additional, Pietrantuono, G., additional, Manni, M., additional, Marcheselli, L., additional, Federico, M., additional, and Versari, A., additional

Published
2021
Full Text
View/download PDF

3. PROGNOSTIC MODEL FOR HIGH TUMOR BURDEN FOLLICULAR LYMPHOMA INCLUDING BASELINE TOTAL METABOLIC TUMOR VOLUME AND END INDUCTION PET: a POOLED ANALYSIS FROM LYSA AND FIL TRIALS

Author

Cottereau, A., primary, Versari, A., additional, Dupuis, J., additional, Chartier, L., additional, Menga, M., additional, Casasnovas, R., additional, Haioun, C., additional, Tilly, H., additional, Tarantino, V., additional, Dubreuil, J., additional, Federico, M., additional, Salles, G., additional, Luminari, S., additional, Trotman, J., additional, and Meignan, M., additional

Published
2017
Full Text
View/download PDF

4. THE RISK OF TRANSFORMATION OF FOLLICULAR LYMPHOMA “TRANSFORMED” BY RITUXIMAB: THE ARISTOTLE STUDY PROMOTED BY THE EUROPEAN LYMPHOMA INSTITUTE

Author

Federico, M., primary, Caballero, D., additional, Marcheselli, L., additional, Tarantino, V., additional, Sarkozy, C., additional, Lopez Guillermo, A., additional, Wondergem, M., additional, Kimby, E., additional, Rusconi, C., additional, Zucca, E., additional, Montoto, S., additional, da Silva, M.G., additional, Aurer, I., additional, Paszkiewicz-Kozik, E., additional, Cartron, G., additional, Morschhauser, F., additional, Alcoceba, M., additional, Chamuleau, M., additional, Lockmer, S., additional, Minoia, C., additional, Issa, D., additional, Alonso, S., additional, Conte, L., additional, Salles, G., additional, and Coiffier, B., additional

Published
2017
Full Text
View/download PDF

5. LONG TERM RESULTS OF THE FOLL05 RANDOMIZED STUDY COMPARING R-CVP WITH R-CHOP AND R-FM AS FIRST LINE THERAPY IN PATIENTS WITH ADVANCED STAGE FOLLICULAR LYMPHOMA. A FIL STUDY

Author

Luminari, S., primary, Tarantino, V., additional, Anastasia, A., additional, Boccomini, C., additional, Chiarenza, A., additional, Rigacci, L., additional, Angelucci, E., additional, Ferrari, A., additional, Pulsoni, A., additional, Rattotti, S., additional, Angrilli, F., additional, Gaidano, G., additional, Stelitano, C., additional, Bertoldero, G., additional, Cascavilla, N., additional, Salvi, F., additional, Ferreri, A.J., additional, Vallisa, D., additional, Balzarotti, M., additional, Cox, M.C., additional, Freilone, R., additional, Marcheselli, L., additional, Dondi, A., additional, Manni, M., additional, and Federico, M., additional

Published
2017
Full Text
View/download PDF

6. POD24 AND CR30 ARE PROMISING SURROGATE ENDPOINTS FOR ASSESSING THE OUTCOME OF PATIENTS WITH ADVANCED STAGE FOLLICULAR LYMPHOMA ENROLLED IN THE FOLL05 TRIAL BY FIL.

Author

Luminari, S., primary, Marcheselli, L., additional, Manni, M., additional, Anastasia, A., additional, Vitolo, U., additional, Chiarenza, A., additional, Rigacci, L., additional, Angelucci, E., additional, Fama, A., additional, Pulsoni, A., additional, Rattotti, S., additional, Angrilli, F., additional, Gaidano, G., additional, Stelitano, C., additional, Bertoldero, G., additional, Cascavilla, N., additional, Salvi, F., additional, Ferreri, A.J., additional, Tarantino, V., additional, Bellei, M., additional, and Federico, M., additional

Published
2017
Full Text
View/download PDF

7. MYD88 L265P mutation and interleukin‐10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study

Author

Ilaria Francaviglia, Paolo Lopedote, Filippo Gagliardi, Fabio Ciceri, Sara Steffanoni, Rita Daverio, Teresa Calimeri, Elena Anghileri, Maria Rosa Terreni, Marianna Sassone, Roberto Furlan, Piera Angelillo, Vittoria Tarantino, Maurilio Ponzoni, Chiara Iacona, Claudio Tripodo, Cristina Belloni, Alessandro Gulino, Daniela De Lorenzo, Massimo Filippi, Marica Eoli, Elena Guggiari, Maria Giulia Cangi, Vittorio Martinelli, Massimo Locatelli, Annamaria Finardi, Andrés J.M. Ferreri, Andrea Falini, Nicoletta Anzalone, Marco Foppoli, Alessandro Nonis, Pietro Mortini, Claudio Doglioni, Angelo Diffidenti, Ferreri, A. J. M., Calimeri, T., Lopedote, P., Francaviglia, I., Daverio, R., Iacona, C., Belloni, C., Steffanoni, S., Gulino, A., Anghileri, E., Diffidenti, A., Finardi, A., Gagliardi, F., Anzalone, N., Nonis, A., Furlan, R., De Lorenzo, D., Terreni, M. R., Martinelli, V., Sassone, M., Foppoli, M., Angelillo, P., Guggiari, E., Falini, A., Mortini, P., Filippi, M., Tarantino, V., Eoli, M., Ciceri, F., Doglioni, C., Tripodo, C., Locatelli, M., Cangi, M. G., Ponzoni, M., Ferreri A.J.M., Calimeri T., Lopedote P., Francaviglia I., Daverio R., Iacona C., Belloni C., Steffanoni S., Gulino A., Anghileri E., Diffidenti A., Finardi A., Gagliardi F., Anzalone N., Nonis A., Furlan R., De Lorenzo D., Terreni M.R., Martinelli V., Sassone M., Foppoli M., Angelillo P., Guggiari E., Falini A., Mortini P., Filippi M., Tarantino V., Eoli M., Ciceri F., Doglioni C., Tripodo C., Locatelli M., Cangi M.G., and Ponzoni M.

Subjects
Adult, Male, Pathology, medicine.medical_specialty, Lymphoma, Biopsy, Concordance, interleukin-10, diffuse large B-cell lymphoma, Mutation, Missense, Central Nervous System Neoplasms, 03 medical and health sciences, primary CNS lymphoma, 0302 clinical medicine, Cerebrospinal fluid, hemic and lymphatic diseases, Biomarkers, Tumor, TaqMan, medicine, Humans, diffuse large B-cell lymphoma, interleukin-10, interleukin-6, MYD88 L265P mutation, primary CNS lymphoma, Prospective cohort study, Aged, medicine.diagnostic_test, business.industry, interleukin-6, Primary central nervous system lymphoma, Hematology, Middle Aged, medicine.disease, Interleukin-10, Neoplasm Proteins, MYD88 L265P mutation, Amino Acid Substitution, 030220 oncology & carcinogenesis, Myeloid Differentiation Factor 88, Female, business, Diffuse large B-cell lymphoma, 030215 immunology
Abstract

Reliable biomarkers are needed to avoid diagnostic delay and its devastating effects in patients with primary central nervous system (CNS) lymphoma (PCNSL). We analysed the discriminating sensitivity and specificity of myeloid differentiation primary response (88) (MYD88) L265P mutation (mut-MYD88) and interleukin-10 (IL-10) in cerebrospinal fluid (CSF) of both patients with newly diagnosed (n=36) and relapsed (n=27) PCNSL and 162 controls (118 CNS disorders and 44 extra-CNS lymphomas). The concordance of MYD88 mutational status between tumour tissue and CSF sample and the source of ILs in PCNSL tissues were also investigated. Mut-MYD88 was assessed by TaqMan-based polymerase chain reaction. IL-6 and IL-10 messenger RNA (mRNA) was assessed on PCNSL biopsies using RNAscope technology. IL levels in CSF were assessed by enzyme-linked immunosorbent assay. Mut-MYD88 was detected in 15/17 (88%) PCNSL biopsies, with an 82% concordance in paired tissue-CSF samples. IL-10 mRNA was detected in lymphomatous B cells in most PCNSL; expression of IL-6 transcripts was negligible. In CSF samples, mut-MYD88 and high IL-10 levels were detected, respectively, in 72% and 88% of patients with newly diagnosed PCNSL and in 1% of controls; conversely, IL-6 showed a low discriminating sensitivity and specificity. Combined analysis of MYD88 and IL-10 exhibits a sensitivity and specificity to distinguish PCNSL of 94% and 98% respectively. Similar figures were recorded in patients with relapsed PCNSL. In conclusion, high detection rates of mut-MYD88 and IL-10 in CSF reflect, respectively, the MYD88 mutational status and synthesis of this IL in PCNSL tissue. These biomarkers exhibit a very high sensitivity and specificity in detecting PCNSL both at initial diagnosis and relapse. Implications of these findings in patients with lesions unsuitable for biopsy deserve to be investigated.

Published
2021

8. Ring 17 syndrome: first clinical report without intellectual disability.

Author

de Palma L, De Carlo D, Lenzini E, Boniver C, Tarantino V, Bacci B, and Vecchi M

Subjects
Adolescent, Cognition, Drug Resistance, Electroencephalography, Epilepsy etiology, Epilepsy psychology, Executive Function, Female, Humans, Neuropsychological Tests, Ring Chromosomes, Syndrome, Chromosomes, Human, Pair 17 genetics, Intellectual Disability psychology
Abstract

Ring chromosomes are rare abnormalities caused by the fusion of the telomeric regions. Three-ring chromosome syndromes (Cr 20, Cr 17 and Cr 14) cause epilepsy with variable phenotypes. In ring 17 patients with mild phenotype, some authors have shown an epilepsy syndrome similar to that of ring 20. We report the first case of a girl with ring chromosome 17 and a normal neurological and general cognitive profile. She had had, from 9 years old, focal pharmacoresistant epilepsy associated with episodes of non-convulsive status epilepticus with mainly autonomic features. Cytogenetic analysis revealed an abnormal karyotype characterised by the presence of de novo ring chromosome 17 in 19% of metaphases. The array CGH (100 KB) did not show any genetic deletion. The clinical and epilepsy phenotype was, to a certain degree, similar to that of ring 20 syndrome.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results